Page last updated: 2024-08-25

bendamustine hydrochloride and Leukemia, Pre-B-Cell

bendamustine hydrochloride has been researched along with Leukemia, Pre-B-Cell in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Heymanns, J; Köppler, H; Pandorf, A; Weide, R	1

Trials

1 trial(s) available for bendamustine hydrochloride and Leukemia, Pre-B-Cell

Article	Year
Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leukemia & lymphoma, 2004, Volume: 45, Issue:12 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Bendamustine Hydrochloride; Disease Progression; Drug Therapy, Combination; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Nitrogen Mustard Compounds; Outpatients; Pilot Projects; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Rituximab; Survival Rate; Time Factors; World Health Organization	2004

Article

Year

Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study.

Leukemia & lymphoma, 2004, Volume: 45, Issue:12

Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Bendamustine Hydrochloride; Disease Progression; Drug Therapy, Combination; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Nitrogen Mustard Compounds; Outpatients; Pilot Projects; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Rituximab; Survival Rate; Time Factors; World Health Organization

2004